Why the study?
Does etanercept improve left ventricular ejection fraction and remodeling in patients with NYHA class III to IV heart failure?
Does etanercept improve left ventricular ejection fraction and remodeling in patients with NYHA class III to IV heart failure?
Etanercept therapy for 3 months in advanced heart failure was safe and resulted in dose-dependent improvements in LV structure and function.
No takes yet. Share an insight, caveat, or question.
Supports etanercept for LV function and remodeling gains in advanced HF; extends anti-TNF therapy to randomized evidence.
Bozkurt et al. (2001) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: